From the Guidelines
Moujjaro is likely referring to a medication, and based on the most recent evidence, it is possible that it is a brand name for a dual GIP and GLP-1 receptor agonist, similar to tirzepatide, which has been shown to have beneficial effects on glycemic control and weight loss 1. However, without more context or information, it is difficult to provide a definitive answer. If Moujjaro is indeed a medication, it is essential to consult the prescribing information and discuss it with a healthcare professional to determine its indications, dosing, and potential side effects. Some key points to consider when evaluating a medication like Moujjaro include:
- Its efficacy in improving glycemic control and weight loss
- Its potential benefits and risks, including effects on cardiovascular outcomes and renal function
- Its dosing and administration, including any necessary titration or monitoring
- Its potential interactions with other medications or foods
- Its side effect profile, including any common or serious adverse events. It is crucial to rely on high-quality, up-to-date evidence when making decisions about medications, and to consult with a healthcare professional to determine the best course of treatment for individual patients 1.
From the FDA Drug Label
MOUNJARO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The main use of Moujjaro (tirzepatide) is as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 2.
- Key points:
- Improve glycemic control
- Adults with type 2 diabetes mellitus
- Used in conjunction with diet and exercise The FDA drug label does provide information on the use of Moujjaro for type 2 diabetes mellitus, but does not provide information on other potential uses of the medication 2.
From the Research
Overview of Moujjaro (Tirzepatide)
- Moujjaro, also known as tirzepatide, is a dual incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors 3, 4.
- It is approved for use as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM) in several countries, including the USA, EU, and Japan 3.
Efficacy of Moujjaro
- Tirzepatide has been shown to be superior to GLP-1 receptor agonists, such as dulaglutide and semaglutide, in terms of glycaemic control and weight loss in adults with inadequately controlled T2DM 3, 4, 5.
- In phase III SURPASS trials, once-weekly subcutaneous tirzepatide was associated with significant reductions in HbA1c and body weight, with a low risk of clinically significant or severe hypoglycaemia 3, 4, 5, 6.
- Tirzepatide was also found to improve insulin sensitivity and insulin secretory responses to a greater extent than semaglutide, and was associated with lower prandial insulin and glucagon concentrations 4.
Safety Profile of Moujjaro
- The safety profile of tirzepatide is consistent with that of GLP-1 receptor agonists, with the most common adverse events being gastrointestinal events, such as nausea, diarrhoea, decreased appetite, and vomiting 3, 4, 5, 6.
- Tirzepatide was not associated with an increased risk of major adverse cardiovascular events, and was found to have a low risk of clinically significant or severe hypoglycaemia 3, 4, 5, 6.
Comparison with Other Treatments
- Tirzepatide has been compared to other treatments, including semaglutide, dulaglutide, and basal insulin, and has been found to be superior in terms of glycaemic control and weight loss 3, 4, 5.
- The efficacy and safety of tirzepatide have been evaluated in several clinical trials, including the SURPASS trials, which have demonstrated its potential as a valuable addition to the treatment options for T2DM 3, 4, 5, 6.